Candriam SCA’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Candriam SCA’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-715	Closed	-$293K	–	856
2018 Q3	$293K	Hold	715	–	–	﹤0.01%	756
2018 Q2	$386K	Hold	715	–	–	0.01%	723
2018 Q1	$329K	Hold	715	–	–	0.01%	715
2017 Q4	$479K	Hold	715	–	–	0.01%	686
2017 Q3	$450K	Buy	+715	New	+$372K	0.01%	677
2017 Q2	–	Sell	-715	Closed	-$536K	–	719
2017 Q1	$536K	Hold	715	–	–	0.01%	644
2016 Q4	$701K	Hold	715	–	–	0.02%	572
2016 Q3	$967K	Hold	715	–	–	0.02%	502
2016 Q2	$626K	Sell	715 -100	-12%	-$133K	0.02%	528
2016 Q1	$1.13M	Sell	815 -85	-9%	-$121K	0.03%	409
2015 Q4	$1.66M	Buy	900 +223	+33%	+$446K	0.04%	326
2015 Q3	$1.32M	Buy	677 +52	+8%	+$122K	0.03%	399
2015 Q2	$1.42M	Hold	625	–	–	0.03%	402
2015 Q1	$1.75M	Buy	+625	New	+$1.64M	0.04%	408

Other funds holding TCON

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Candriam SCA's TCON Position: Q4 2018 in Review

Candriam SCA sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2018, closing a stake of 715 shares — an estimated $293K sold.

Candriam SCA first reported a position in TCON in Q1 2015 and held it in 14 quarters. The position peaked at $1.75M in Q1 2015. 27 funds tracked by Wall St. Rank hold TCON as of Q4 2018.

Candriam SCA reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Candriam SCA sold 715 TRACON Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $293K.
Candriam SCA first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 14 quarters.
Candriam SCA's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $1.75M in Q1 2015.
27 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Candriam SCA's 13F filing for Q4 2018, filed 14 Feb 2019.